The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet

Diabetes

Volumn 45, Issue 1, 1996, Pages 60-66

  Stevenson, Ralph W ^a   McPherson, R Kirk ^a   Persson, Lorna M ^a   Genereux, Paul E ^a   Swick, Andrew G ^a   Spitzer, Josephine ^a   Herbst, John J ^a   Andrews, Kim M ^a   Kreutter, David K ^a   Gibbs, E Michael ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; ENGLITAZONE; GLUCOSE TRANSPORTER; INSULIN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; DRUG EFFECT; EPIDIDYMIS FAT; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLYCOGEN LIVER LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 13344261983     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.1.60     Document Type: Article

References (42)

1. Ip C, Tepperman HM, DeWitt J, Tepperman J: The effect of diet fat on rat adipocyte glucose transport. Horm Metab Res 9:218-222, 1977
2. Hissin PJ, Karnieli E, Simpson IA, Salans LB, Cushman SW: A possible mechanism of insulin resistance in the rat adipose cell with high-fat/low-carbohydrate feeding: depletion of intracellular glucose transport systems Diabetes 31:589-592, 1982
3. Kahn BB: Faculiative glucose transporters: regulatory mechanisms and dysregulation in diabetes. J Clin Invest 89:1367-1374, 1992
4. Kreutter DK, Andrews KM, Gibbs EM, Hutson NJ, Stevenson RW: Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes. Diabetes 39.1414-1419, 1990
5. Gibbs EM, Genereux PE, Kreutter DK, Andrews KM, Stevenson RW: A novel antidiabetic agent, CP-68,722, increases levels of glucose transport and glucose transporter protein in 3T3-L1 adipocytes (Abstract). Diabetologio 32:491A, 1989
6. Stevenson RW, Hutson NJ, Krupp MN, Volkmann, RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, Gibbs EM, Kreutter DK: Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 39:1218-1227, 1990
7. Hargrove DM, Kreutter DK, Gibbs EM, Stevenson RW: The mechanism of action of thiazolidiedione antidiabetic agents. In Frontiers in Diabetes Research. Vol. 7, Shafrir E, Ed. Smith-Gordon, U.K., 1990. p 313-319
8. Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW: Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 251:E576-E583, 1986
9. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH: Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40:1397-1403, 1991
10. Stevenson RW, McPherson RK, Genereux PE, Danbury BH, Kreutter DK: Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 40:1268-1274, 1991
11. Brunk CF, Jones KC, James TW: Assay for nanogram quantities of DNA in cellular homogenates. Anal Biochem 92:497-500, 1979
12. Lamphere M, Carpenter CL, Sheng Z, Kallen RG, Lienhard GE: Activation of PI 3-kinase in 3T3-L1 adipocytes by association with insulin receptor substrate-1. Am J Physiol 266:E486-E489, 1994
13. Herbst JJ, Andrews G, Contillo L, Lamphere L, Gardner J, Lienhard GE, Gibbs EM: Potent activation of phosphatidylinositol 3′-kinase by simple phosphotyrosine peptides derived from insulin receptor substrate 1 containing two YMXM motifs for binding SH2 domains. Biochemistry 33:9370-9381, 1994
14. Brant AM, McCoid SC, Thomas HM, Baldwin SA, Davies A, Parker JC, Gibbs EM, Gould GW: Analysis of the glucose transporter content of islet cell lines: implications for glucose-stimulated insulin release. Cell Signalling 4:641-650, 1992
15. Schroer DW, Frost SC, Kohanski RA, Lane MD, Lienhard GE Identification and partial purification of the insulin-responsive glucose transporter from 3T3-L1 adipocytes. Biochim Biophys Acta 880:317-326, 1986
16. Lamphere L, Lienhard GE: Components of signaling pathways for insulin and insulin-like growth faclor-I in muscle myoblasts and myotubes. Endocrinology 131-2196-2202, 1992
17. Bradford MM: A rapid and sensitive method for the Quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
18. Holman GD, Kozka IJ, Clark AE, Flower CJ, Saltis J, Habberfield AD, Simpson LA, Cushman SW: Cell surface labeling of glucose transporter isoform GLUT4 by bis-mannosc photolabel. J Biol Chem 265:18172-18179, 1990
19. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW: Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipid Diabetes 40:280-289, 1991
20. Borkman M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV The relationship between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 328:238-244, 1993
21. Pedersen O, Kahn CR, Flier JS, Kahn BB: High-fat feeding causes insulin resistance and a marked decrease in the expression of glucose transporters (Glut4) in fat cells of rats. Endocrinology 129:771-777, 1991
22. Hofmann C, Lorenz K, Colca JR: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone Endocrinology 129:1915-1925, 1901
23. Gibbs EM, Banker MJ, McCoid SC, Genereux PE, Pereira DA: Differential regulation of GLUT1 and GLUT4 mRNA by the antidiabetic agent englitazone (Abstract). Diabetes 41 (Suppl. 1):202A, 1992
24. Stevenson RW, Gibbs EM, Parker JC, Shulman GI, Kessedjian M-J, Reynolds JA, Kreutter DK: Thiazolidinedione antidiabetics. In Lessons from Animal Diabetes. Vol. 5. Shafrir E, Ed. Smith-Gordon, U.K., 1994, p. 181-195
25. Bourey RE, Koranyi L, James DE, Mueckler M, Permutt MA Effects of altered glucose homeostasis on glucose transporter expression in skeletal muscle of the rat. J Clin Invest 86:542-547, 1990
26. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43.1203-1210, 1994
27. Sun XJ, Rothernberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73-77, 1991
28. Okada T, Kawano Y, Sakakibara T, Hazeko O, Ui M: Essential role of phosphatidylinositol-3′-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. J Biol Chem 269:3568-3573, 1994
29. Zhang B, Szalkowski D, Diaz E, Hayes N, Smith R, Berger J: Potentiation of insulin stimulation of phosphatidylinositol-3′-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. J Biol Chem 269:25735-25741, 1994
30. McPherson RK, Gibbs EM, Treadway JL, Stevenson RW: Englitazone effects on signal transduction and metabolic responses to insulin and glucagon in isolated rat hepatocytes (Abstract), Diabetes 42 (Suppl 1):36A, 1993
31. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186, 1994
32. Araki E, Lipes MA, Patti M-E, Bruning JC, Haag B III, Johnson RS, Kahn CR: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190, 1994
33. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, DeFronzo RA: The disposal of an oral glucose load in healthy subjects A quantitative study. Diabetes 34:580-588, 1985
34. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zych K, Ferrannini E. DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213, 1989
35. Bowen LB, Stein PP, Stevenson RW, Shulman GI: The effect of CP-68,722, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40:1538-1544, 1991
36. Blackmore PF, McPherson RK, Stevenson RW: Actions of the novel antidiabetic agent englitazone in rat hepatocytes. Metabolism 42:1583-1587, 1993
37. Kong X, Manchester J, Salmons S, Lawrence JC Jr: Glucose transporters in single skeletal muscle fibers. Relationship to hexokinase and regulation by contractile activity. J Biol Chem 269.12963-12967, 1994
38. Weinstein SP, Holand A, O'Boyle E, Haber RS: Thiazolidinediones ameliorate glucocorticoid-induced insulin resistance in rat skeletal muscle without changing GLUT4 glucose transporter protein content (Abstract). Diabetes 41 (Suppl. 1):106A, 1992
39. Stevenson RW, Gibbs EM, Kreutter DK, McPherson RK, Clark DA, Hulin B, Goldstein SW, Parker JC, Swick AG, Treadway JL, Hargrove DM, Shulman GI: The thiazolidinedione drug series. In Diabetes Annual. Vol. 9. Marshall SM, Home PD, Rizza RA, Eds. Amsterdam, Elsevier Science, 1995, p. 175-191
40. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu V, Iwatsuka H, Suzuoki Z: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)-benzyl]-thiazolidine-2,4-di-one] (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent Diabetes 32:804-810, 1983
41. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
42. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331 1188-1193, 1994